2-Methylene 19-nor-25-dehydro-1α-hydroxyvitamin D3 26,23-lactones:: Synthesis, biological activities and molecular basis of passive antagonism

被引:23
作者
Yoshimoto, Nobuko [2 ,3 ]
Inaba, Yuka [1 ,2 ,3 ]
Yamada, Sachiko [1 ]
Makishima, Makoto [1 ]
Shimizu, Masato [2 ]
Yamamoto, Keiko [3 ]
机构
[1] Nihon Univ, Dept Biochem, Itabashi Ku, Tokyo 1738610, Japan
[2] Tokyo Med & Dent Univ, Sch Biomed Sci, Tokyo 1010062, Japan
[3] Showa Pharmaceut Univ, Lab Drug Design & Med Chem, Tokyo 1948543, Japan
关键词
vitamin D receptor; antagonist; partial agonist; transactivation; nuclear receptor; vitamin D; passive antagonist;
D O I
10.1016/j.bmc.2007.09.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To investigate the molecular mechanism of vitamin D receptor (VDR) antagonists having no structurally bulky group interfering with helix 12 of the ligand-binding domain of the VDR, we have synthesized four diastereomers at C(20) and C(23) of 19-nor-1 alpha-hydroxyvitamin D-3 25-methylene-26,23-lactone bearing a 2MD-type A-ring. All four analogs showed significant VDR affinity. Transactivation was tested by using Cos7 cells and HEK293 cells. In both types of cells, LAC67a showed little transactivation potency and inhibited the activation induced by the natural hormone concentration-dependently, indicating that LAC67a works as an antagonist for the VDR in these cells. LAC67b, LAC82a and LAC82b similarly acted as VDR antagonists in Cos7 cells, but in HEK293 cells they behaved as potent VDR agonists. Docking of four lactones into the VDR-LBD, followed by structural analysis, demonstrated that each lactone lacks the hydrophobic interaction with helix12 necessary for maintaining the active conformation of the VDR, indicating that these lactones are passive-type antagonists. Furthermore, each docking structure explained the characteristic transactivation profiles of the four lactones. On the basis of our present findings, we suggest that the ligand acts as an agonist if there are appropriate coactivators in the cells to bind to the looser VDR-ligand complex, and as an antagonist if there are no such appropriate coactivators. The molecular basis of the passive antagonism is discussed in detail. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:457 / 473
页数:17
相关论文
共 40 条
[31]   New 1α,25-dihydroxy-19-norvitamin D3 compounds of high biological activity:: Synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues [J].
Sicinski, RR ;
Prahl, JM ;
Smith, CM ;
DeLuca, HF .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (23) :4662-4674
[32]   Bacterial expression and characterization of the ligand-binding domain of the vitamin D receptor [J].
Strugnell, SA ;
Hill, JJ ;
McCaslin, DR ;
Wiefling, BA ;
Royer, CA ;
DeLuca, HF .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1999, 364 (01) :42-52
[33]   Synthesis and structure-activity relationships of TEI-9647 derivatives as Vitamin D3 antagonists [J].
Takenouchi, K ;
Sogawa, R ;
Manabe, K ;
Saitoh, H ;
Gao, Q ;
Miura, D ;
Ishizuka, S .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 89-90 (1-5) :31-34
[34]   Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification [J].
Tocchini-Valentini, G ;
Rochel, N ;
Wurtz, JM ;
Moras, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (08) :1956-1961
[35]   Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands [J].
Tocchini-Valentini, G ;
Rochel, N ;
Wurtz, JM ;
Mitschler, A ;
Moras, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (10) :5491-5496
[36]   New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 with conformationally restricted side chains:: Evaluation of biological activity and structural determination of VDR-bound conformations [J].
Vanhooke, Janeen L. ;
Padmaja Tadi, Bulli ;
Benning, Matthew M. ;
Plum, Lori A. ;
DeLuca, Hector F. .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2007, 460 (02) :161-165
[37]   Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide [J].
Vanhooke, JL ;
Benning, MM ;
Bauer, CB ;
Pike, JW ;
DeLuca, HF .
BIOCHEMISTRY, 2004, 43 (14) :4101-4110
[38]   Conformationally restricted analogs of 1 alpha,25-dihydroxyvitamin D-3 and its 20-epimer: Compounds for study of the three-dimensional structure of vitamin D responsible for binding to the receptor [J].
Yamamoto, K ;
Sun, WY ;
Ohta, M ;
Hamada, K ;
DeLuca, HF ;
Yamada, S .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (14) :2727-2737
[39]   Three-dimensional modeling of and ligand docking to vitamin D receptor ligand binding domain [J].
Yamamoto, K ;
Masuno, H ;
Choi, M ;
Nakashima, K ;
Taga, T ;
Ooizumi, H ;
Umesono, K ;
Sicinska, W ;
VanHooke, J ;
DeLuca, HF ;
Yamada, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1467-1472
[40]   Culture serum-induced conversion from agonist to antagonist of a Vitamin D analog, TEI-9647 [J].
Yamaoka, Kazuyoshi ;
Kim, Mi-sun ;
Takada, Ichiro ;
Takeyama, Ken-ichi ;
Kamimura, Takashi ;
Kato, Shigeaki .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2006, 100 (4-5) :177-183